Tuberculosis
ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
Published in TB and Outbreaks Week, March 11th, 2008
Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, as a result of growing interest from prospective buyers, announced a development strategy for further advancement of the company's proprietary benzoxazinorifamycins as leading antibacterial drug candidates in combination antibiotic therapy. Rifalazil is the most developed of these compounds, though most of the interest for combination antibiotics has centered on novel compounds or new chemical entities ("NCEs").
Combination antibiotic therapy has been used as the treatment of choice for certain stubborn bacterial infections. Two prime examples are tuberculosis and gastric ulcer disease,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Biochemistry
Research results from S.H. Newman and co-authors update knowledge of biochemistry - Dengue Fever
New findings reported from R.M.R. Nogueira and co-authors describe advances in dengue fever - Flu Vaccines
New findings in flu vaccines described by H. Jin and co-researchers - Fusion Proteins
Study findings from X.L. Hou et al provide new insights into fusion proteins - Genetics & Genomics
Study data from V.M. Kovalenko et al provide new insights into genetics & genomics - Hantavirus
Data on hantavirus reported by A. Markotic and co-researchers - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
